Simultaneous treatment with azelnidipine and olmesartan inhibits apoptosis of hl-1 cardiac myocytes expressing e334k CMYBPC

Drug Research

Volumn 63, Issue 10, 2013, Pages 515-520

  Bahrudin, U ^a,b   Ikeda, N ^a   Utami, S B ^a,b   Maharani, N ^a,b   Morikawa, K ^a   Li, P ^a   Sobirin, M A ^b   Hasegawa, A ^a   Sakata, S ^a   Endo, R ^a   Rifqi, S ^b   Shirayoshi, Y ^a   Yamamoto, K ^c   Ninomiya, H ^c   Hisatome, I ^a  

^a TOTTORI UNIVERSITY   (Japan)

^b DIPONEGORO UNIVERSITY   (Indonesia)

^c TOTTORI UNIVERSITY   (Japan)

Author keywords

angiotensin receptor blocker; apoptosis; calcium channel blocker; hypertrophic cardiomyopathy; mutant cardiac myosin binding protein C

Indexed keywords

AMLODIPINE; AZELNIDIPINE; BEPRIDIL; BETA ACTIN; CARVEDILOL; CYTOCHROME C; LIPOCORTIN 5; OLMESARTAN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN P53; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR E334K CMYBPC; UNCLASSIFIED DRUG; VALSARTAN;

ANIMAL CELL; APOPTOSIS; ARTICLE; COMPARATIVE STUDY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; FLOW CYTOMETRY; HEART MUSCLE CELL; HYPERTROPHIC CARDIOMYOPATHY; NONHUMAN; PROTEIN EXPRESSION; RAT;

EID: 84886831240     PISSN: 21949379     EISSN: 21949387     Source Type: Journal    
DOI: 10.1055/s-0033-1347188     Document Type: Article

References (38)

1. Seidman J. G., Seidman C. The genetic basis for cardiomyopathy: from mutation identification to mechanistic paradigms. Cell: 2001; 104 557 567
2. Anselmi A., Gaudino M., Baldi A. et al. Role of apoptosis in pressure-overload cardiomyopathy. J Cardiovasc Med: 2008; 9 227 232
3. Gersh B. J., Maron B. J., Bonow R. O. et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. Circulation: 2011; 124 e783 e831
4. Ni L., Zhou C., Duan Q. et al. β-AR blockers suppresses ER stress in cardiac hypertrophy and heart failure. PLoS One: 2011; 6 e27294
5. Lakshmanan A. P., Thandavarayan R. A., Palaniyandi S. S. et al. Modulation of AT-1R/CHOP-JNK-Caspase12 pathway by olmesartan treatment attenuates ER stress-induced renal apoptosis in streptozotocin-induced diabetic mice. Eur J Pharm Sci: 2011; 44 627 634
6. Kain V., Kumar S., Sitasawad S. L. Azelnidipine prevents cardiac dysfunction in streptozotocin-diabetic rats by reducing intracellular calcium accumulation, oxidative stress and apoptosis. Cardiovasc Diabetol: 2011; 10 1 10
7. Bahrudin U., Morisaki H., Morisaki T. et al. Ubiquitin-proteasome system impairment caused by a missense cardiac myosin-binding protein C mutation and associated with cardiac dysfunction in hypertrophic cardiomyopathy. J Mol Biol: 2008; 384 896 907
8. Bahrudin U., Morikawa K., Takeuchi A. et al. Impairment of ubiquitin-proteasome system by E334K cMyBPC modifies channel proteins, leading to electrophysiological dysfunction. J Mol Biol: 2011; 4134 857 878
9. White S. M., Constantin P. E., Claycomb W. C. Cardiac physiology at the cellular level: use of cultured HL-1 cardiomyocytes for studies of cardiac muscle cell structure and function. Am J Physiol Heart Circ Physiol: 2004; 286 H823 H829
10. Jinno T., Iwai M., Li Z. et al. Calcium channel blocker azelnidipine enhances vascular protective effects of AT1 receptor blocker olmesartan. Hypertension: 2004; 43 263 269
11. Iwai M., Chen R., Ide A. et al. The calcium-channel blocker, azelnidipine, enhances the inhibitory action of AT1 receptor blockade on ischemic brain damage. J Hypertens: 2006; 24 2023 2031
12. Ohyama T., Sato K., Kishimoto K. et al. Azelnidipine is a calcium blocker that attenuates liver fibrosis and may increase antioxidant defence. Br J Pharmacol: 2012; 165 1173 1187
13. Ohlstein E. H., Douglas S. A., Sung C. P. et al. Carvedilol, a cardiovascular drug, prevents vascular smooth muscle cell proliferation, migration, and neointimal formation following vascular injury. Proc Natl Acad Sci USA: 1993; 90 6189 6193
14. Willette R. N., Aiyar N., Yue T. L. et al. In vitro and in vivo characterization of intrinsic sympathomimetic activity in normal and heart failure rats. J Pharmacol Exp Ther: 1999; 289 48 53
15. Beaughard M., Ferrier M., Labrid C. et al. Studies on the bradycardia induced by bepridil. Br J Pharmacol: 1982; 75 293 300
16. Ma J., Kishida S., Wang G. Q. et al. Comparative effects of azelnidipine and other Ca2+-channel blockers on the induction of inducible nitric oxide synthase in vascular smooth muscle cells. J Cardiovasc Pharmacol: 2006; 47 314 321
17. Criscione L., de Gasparo M., Bühlmayer P. et al. Pharmacological profile of valsartan: a potent, orally active, nonpeptide antagonist of the angiotensin II AT1-receptor subtype. Br J Pharmacol: 1993; 110 761 771
18. Brunelle J. K., Letai A. Control of mitochondrial apoptosis by the Bcl-2 family. J Cell Sci: 2009; 122 437 441
19. Sawada T., Yamada H., Shiraishi J. et al. Combination Effect of Calcium Channel Blocker and Valsartan on Cardiovascular Event Prevention in Patients with High-Risk Hypertension: Ancillary Results of the KYOTO HEART Study. Clin Exp Hypertens: 2012; 34 153 159
20. Okada K., Minamino T., Tsukamoto Y. et al. Prolonged endoplasmic reticulum stress in hypertrophic and failing heart after aortic constriction: possible contribution of endoplasmic reticulum stress to cardiac myocyte apoptosis. Circulation: 2004; 110 705 712
21. Tanaka T., Nangaku M., Miyata T. et al. Blockade of calcium influx through L-type calcium channels attenuates mitochondrial injury and apoptosis in hypoxic renal tubular cells. J Am Soc Nephrol: 2004; 15 2320 2333
22. Yue T. L., Ma X. L., Wang X. et al. Possible involvement of stress-activated protein kinase signaling pathway and Fas receptor expression in prevention of ischemia/reperfusion-induced cardiomyocyte apoptosis by carvedilol. Circ Res: 1998; 82 166 174
23. Zeng H., Liu X., Zhao H. Effects of carvedilol on cardiomyocyte apoptosis and gene expression in vivo after ischemia-reperfusion in rats. J Huazhong Univ Sci Technolog Med Sci: 2003; 23 127 130
24. Schwarz E. R., Kersting P. H., Reffelmann T. et al. Cardioprotection by Carvedilol: antiapoptosis is independent of beta-adrenoceptor blockage in the rat heart. J Cardiovasc Pharmacol Ther: 2003; 8 207 215
25. Chandar S., Yeo L. S., Leimena C. et al. Effects of mechanical stress and carvedilol in lamin A/C-deficient dilated cardiomyopathy. Circ Res: 2010; 106 573 582
26. Yamamoto E., Dong Y. F., Kataoka K. et al. Olmesartan prevents cardiovascular injury and hepatic steatosis in obesity and diabetes, accompanied by apoptosis signal regulating kinase-1 inhibition. Hypertension: 2008; 52 573 580
27. Sukumaran V., Watanabe K., Veeraveedu P. T. et al. Olmesartan, an AT1 antagonist, attenuates oxidative stress, endoplasmic reticulum stress and cardiac inflammatory mediators in rats with heart failure induced by experimental autoimmune myocarditis. Int J Biol Sci: 2011; 7 154 167
28. Fujimoto S., Satoh M., Horike H. et al. Olmesartan ameliorates progressive glomerular injury in subtotal nephrectomized rats through suppression of superoxide production. Hypertens Res: 2008; 31 305 313
29. Yu G., Liang X., Xie X. et al. Diverse effects of chronic treatment with losartan, fosinopril, and amlodipine on apoptosis, angiotensin II in the left ventricle of hypertensive rats. Int J Cardiol: 2001; 81 123 129
30. Ogino A., Takemura G., Kanamori H. et al. Amlodipine inhibits granulation tissue cell apoptosis through reducing calcineurin activity to attenuate postinfarction cardiac remodeling. Am J Physiol Heart Circ Physiol: 2007; 293 H2271 H2280
31. Yamanaka S., Tatsumi T., Shiraishi J. et al. Amlodipine inhibits doxorubicin-induced apoptosis in neonatal rat cardiac myocytes. J Am Coll Cardiol: 2003; 41 870 878
32. Xiang Y., Huang J. Effect of valsartan and fosinopril on catecholamine-induced cardiac hypertrophy. Acta Pharmacol Sin: 2000; 1 850 854
33. Li W., Sun N., Liu W. et al. Influence of valsartan on myocardial apoptosis in spontaneously hypertensive rats. Chin Med J: 2002; 15 364 366
34. Sawicki G., Jugdutt B. I. Valsartan reverses post-translational modifications of the delta-subunit of ATP synthase during in vivo canine reperfused myocardial infarction. Proteomics: 2007; 7 2100 2110
35. Wu T., Dong Z., Geng J. et al. Valsartan protects against ER stress-induced myocardial apoptosis via CHOP/Puma signaling pathway in streptozotocin-induced diabetic rats. Eur J Pharm Sci: 2011; 42 496 502
36. Tanifuji C., Suzuki Y., Geot W. M. et al. Beneficial effects of combination therapy with olmesartan and azelnidipine in murine polycystic kidneys. Kidney Blood Press Res: 2009; 32 239 249
37. Hosoya M., Ohashi J., Sawada A. et al. Combination therapy with olmesartan and azelnidipine improves EDHF-mediated responses in diabetic apolipoprotein E-deficient mice. Circ J: 2010; 74 798 806
38. Abe M., Maruyama N., Okada K. et al. Additive antioxidative effects of azelnidipine on angiotensin receptor blocker olmesartan treatment for type 2 diabetic patients with albuminuria. Hypertens Res: 2011; 34 935 941 Technology